The Declaration of Helsinki deals with clinical research in human beings, not a transcendental topic within the realm of business ethics. It is here addressed because it has a long and meaningful history, representing one of the most central documents of human ethics anywhere. Fundamentally, also because the last version, approved in 2024, expanding less prominent shifts in previous documents, does not restrict itself to the intricacies of the research protocols. It thinks out of the box, indirectly approaching such crucial points as digital health, globalization of trials, vulnerable populations, and rare diseases. More importantly, it constantly emphasizes the empowerment of the patients, who should be put at the fulcrum of all decisions and initiatives, even those concerning the setting of research priorities, not merely as bystanders. It also hints at sustainable financing, a point further elucidated by a World Health Organization guidance of 2024. These novelties coincide with several cornerstones and quintessential principles of business ethics in healthcare, namely, the positioning of the human being (patient, consumer, client, beneficiary) and his/her handling (treatment, marketing, monitoring, sales, short or long-term care) away from exploitation, mercantilism, and mishandling, towards protection of social equity and justice.